Dermata Therapeutics (DRMA)
Developing Bioneedle-based skincare for consumer and professional channels.
Something off on this page? Send us feedback.
Develops a direct-to-consumer and professional skincare line around Bioneedle, a freshwater-sponge-derived powder. Intended revenue begins with Tome Foundational Treatment, leaving execution dependent on an uncommercialized launch, outsourced operations, and an exclusive Russian raw-material supplier.
Builds the Tome skincare line around Bioneedle, a purified powder derived from freshwater Spongilla. Its first planned product, Tome Foundational Treatment, is a once-weekly cosmetic skin-renewal treatment; a Clearing Treatment that pairs Bioneedle with a daily salicylic-acid wipe remains in development.
Intends to sell through direct-to-consumer e-commerce and to aestheticians and dermatologists, with U.S.-centered operations and international supply and patent activity. The company applies experience from prior prescription-drug development to consumer and professional skincare, while outsourcing supply, manufacturing, distribution, delivery, and IT.
Commercial execution depends on acceptance of an initial product that had not yet generated sales, an exclusive Russian source for Spongilla raw material, and compliance with cosmetic and OTC claims, manufacturing, and labeling requirements.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.4M · Total debt $0 · Total assets $5.3M · Shareholders' equity $3.5M
- Revenue
- $0
- Operating income
- −$3.0M
- Net income
- −$3.0M
No dividends on record.
| Institutions | 3.05% | 122.5K shares | |
|---|---|---|---|
| 13 holders · as of Jun 30, 2026 | |||
| Insiders | 34.31% | 1.38M shares | |
| 5 holders · as of Aug 18, 2026 | |||
| Other | 62.64% | 2.52M shares | |
| remainder | |||
4.02M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (4.02M in the company's Sep 23, 2026 report, 681.6K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gerald T. Proehl1Insiderdirector, 10 percent owner, officer: PRESIDENT, CHAIRMAN, CEO | 21.50% | 694,687 | filed Aug 18, 2026 |
Kyri K. van Hoose2Insiderofficer: SVP, CFO | 12.09% | 384,352 | filed Aug 18, 2026 |
Geode Capital Management, LLCInstitution | 0.50% | 20,203 | as of Jun 30, 2026 |
Welch & Forbes LLCInstitution | 0.50% | 20,000 | as of Jun 30, 2026 |
Mary FisherInsiderdirector | 0.49% | 19,695 | filed Jan 23, 2025 |
- Gerald T. Proehl's transaction reports restate only vehicles that traded; the 2026 ownership statement (694.7K) plus the 170.1K net shares acquired since is used instead.
- Kyri K. van Hoose's transaction reports restate only vehicles that traded; the 2026 ownership statement (384.4K) plus the 102.0K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 16, 2026 | Kathleen D. Scott | director | −11 | $1.19 |
| Feb 17, 2026 | Munera Maria E. Bedoya-Toro | officer: SVP, Regulatory Affairs | +1,000 | $1.27 |
- Kenvue
Mass-retail Neutrogena acne and renewal lines capture the same spend.
- Hims & Hers Health
Apostrophe teledermatology diverts DTC acne-seeking consumers.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dermata Therapeutics | $1.10 | −1.78% | $783.8K | — | — | — | — |
| Kenvue | $17.67 | −0.03% | $34.29B | 20.5 | 14.8 | 2.2 | +3.0% |
| Hims & Hers Health | $28.48 | +0.32% | $6.79B | — | 132.0 | 2.6 | +38.3% |
| Median | 20.5 | 73.4 | 2.4 | +20.6% |